Product Name: QIK (263-277)
Product Number: PE-01AYQ99
| Size: | 200 µg | Price: | 51.00 | |
| 1 mg | $US | 102.00 | ||
| 5 mg | 224.00 |
Peptide Name: QIK (263-277)
Product Use: Services as a blocking peptide for use with the SIK2-2 rabbit polyclonal antibody (Cat. No.: AB-NK249-2) that is also available from Kinexus. The peptide sequence is located in the kinase catalytic domain last alpha-chain.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CAQIKEHKWMLIEVPV
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1923.3 Da
Peptide Purity Percent after Synthesis and Purification: >95
Product Use: Services as a blocking peptide for use with the SIK2-2 rabbit polyclonal antibody (Cat. No.: AB-NK249-2) that is also available from Kinexus. The peptide sequence is located in the kinase catalytic domain last alpha-chain.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CAQIKEHKWMLIEVPV
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1923.3 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: QIK pan-specific antibody (Cat. No.: AB-NK249-2)
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: QIK pan-specific antibody (Cat. No.: AB-NK249-2)
Scientific Background: SIK2 (QIK) is a protein-serine/threonine kinase of the CAMK group and CAMKL family. It is a member of the salt-inducible kinase family. SIK2 may modulate the efficiency of insulin signal transduction, and affect insulin resistancy. It is activated by phosphorylation on T175 by LKB1 (STK11) in complex with STE20-related adapter-alpha (STRAD alpha) pseudo kinase and CAB39. It stimulates histone deacetylases export. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation, and may be a potential target for therapy in ovarian cancer.
© Kinexus Bioinformatics Corporation 2017